Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Capecitabine in Advanced Malignancies (m-TOR)
NCT01079702Phase 2Unknown
- Sponsor
- University of Amsterdam
- Start
- Apr 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in malignant neoplasms (advanced stage), sponsored by University of Amsterdam. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Status: unknown.
02
Drugs
everolimus
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT01079702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079702.